ResMed Inc. RMD
Verdict: Hold. Fair value $254 against a price of $250 on 6 Jan 2026, 2% above the price.
In plain words
The case for: Narrow competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. Operating Cash Flow was significantly lower than Net Income in FY2022 and FY2023, with OCF/NI....
Main risks
- Decelerating Revenue Growth: Annual revenue growth has slowed from 17.9% to 9.8% over the past three periods, which could signal market maturation or intensifying competition.
- Data Gaps Limit Analysis: The absence of historical balance sheet data and gross margin figures necessitates heavy use of proxies (especially for ROIIC), reducing the precision of the analysis.
- Unsustainable FCF Acceleration?: Free cash flow has grown nearly 9x in three years (from $0.20B to $1.76B TTM). While excellent, the sustainability of this dramatic improvement in cash conversion warrants scrutiny.
- Operating Cash Flow was significantly lower than Net Income in FY2022 and FY2023, with OCF/NI...
- Intense competitive environment
- Operating Cash Flow was significantly lower than Net Income in FY2022 and FY2023, with OCF/NI ratios of 0.45 and 0.77 respectively. This indicates that a large portion of reported earnings was tied up in non-cash working capital, suggesting potential issues with inventory management or receivables collection during that period.